| answer text |
<p>The National Institute for Health and Care Excellence (NICE) and NHS England are
in dialogue with Vertex Pharmaceuticals around access to their portfolio of cystic
fibrosis medicines. It is critical that Vertex now re-engages fully with the NICE
appraisal process and gives serious consideration to the portfolio deal offer that
NHS England made at the end of July. This deal would provide immediate access for
patients to all Vertex licensed medicines and future pipeline products once licensed
and in advance of the individual NICE appraisals concluding.</p>
|
 |
